WHO Issues Alert Over Severe Scarcity of Obesity Injections
Under a tenth of patients who could benefit from obesity jabs including Wegovy have access to them, states the WHO as it issues its first advice on the medications.
With in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is calling for increased and just availability to these injectable treatments.
Based on projections, more than two billion are projected to be obese by 2030 if no action is taken.
"The latest guidance recognises that obesity is a long-term condition that can be treated with holistic and lifelong care," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and logistical bottlenecks are major obstacles to widespread availability to the jabs that can help people shift significant body mass, says the agency.
Skinny Jab Scarcity
Even in the current most favorable case, the production of GLP-1 therapies would only suffice for approximately 100 million people – less than 10% of the global need, according to the health organization.
The advice urges governments and firms to widen access, through strategies such as voluntary licensing.
A patent on semaglutide – the core component of a leading brand – is scheduled to end in a number of countries in 2026.
The Way Obesity Jabs Work
These medications mimick a natural hormone to slow digestion, suppress the appetite and increase the sense of being full so individuals eat less.
Individuals commonly start to lose weight after several weeks of commencing the once-weekly jabs.
Evidence points to users may see weight return within a year of stopping the medication, as their typical appetite resume.
To be above a healthy weight raises your likelihood for developing health problems, such as diabetes, cardiovascular issues, stroke, and some malignancies.
Obesity affects individuals in every country and was responsible for over three and a half million fatalities worldwide in 2024, as per the health agency.
